What is the equity of Taiko Pharmaceutical Co this year?
Taiko Pharmaceutical Co has equity of 6.74 B JPY this year.
In 2024, Taiko Pharmaceutical Co's equity was 6.74 B JPY, a -16.22% increase from the 8.04 B JPY equity in the previous year.
Taiko Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Taiko Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Taiko Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Taiko Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Taiko Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Taiko Pharmaceutical Co has equity of 6.74 B JPY this year.
The equity of Taiko Pharmaceutical Co has increased/decreased by -16.22% decreased compared to the previous year.
A high equity is advantageous for investors of Taiko Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Taiko Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Taiko Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Taiko Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Taiko Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.
The equity of Taiko Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Taiko Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Taiko Pharmaceutical Co paid a dividend of 23.67 JPY . This corresponds to a dividend yield of about 5.84 %. For the coming 12 months, Taiko Pharmaceutical Co is expected to pay a dividend of 0 JPY.
The current dividend yield of Taiko Pharmaceutical Co is 5.84 %.
Taiko Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, January.
Taiko Pharmaceutical Co paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
Taiko Pharmaceutical Co is assigned to the 'Health' sector.
To receive the latest dividend of Taiko Pharmaceutical Co from 3/31/2021 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 12/29/2020.
The last dividend was paid out on 3/31/2021.
In the year 2023, Taiko Pharmaceutical Co distributed 0 JPY as dividends.
The dividends of Taiko Pharmaceutical Co are distributed in JPY.
Our stock analysis for Taiko Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taiko Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.